Pembrolizumab is a highly selective IgG4-kappa humanized monoclonal antibody against PD-1 receptors. It was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. It contains 32 cysteine residues and the complete folded molecule includes 4 disulfide linkages as interchain bonds and 23 interchain bonds. It was developed by Merck & Co and first approved for the treatment of metastatic malignant melanoma by the FDA on September 4, 2014, becoming the first approved therapy against PD-1. In the time since its initial approval, pembrolizumab has been granted approval in the treatment of a wide variety of cancers.
Pembrolizumab is indicated for the following conditions:
For all approved adult indications, pembrolizumab may be used for an additional 6 weeks at 400mg weekly.
John Theurer Cancer Center-Hackensack Meridian Health, Hackensack, New Jersey, United States
Johns Hopkins, Baltimore, Maryland, United States
BIDMC, Boston, Massachusetts, United States
MD Anderson, Houston, Texas, United States
The University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
The University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
University Hospital Essen, Department of Dermatology, Skin Cancer Center, Essen, North Rhine-Westphalia, Germany
HELIOS Klinikum Krefeld, Krefeld, North Rhine-Westphalia, Germany
Universitätsklinikum Gießen und Marburg GmbH, Klinik für Dermatologie und Allergologie, Gießen, Hessen, Germany
Yale New Haven Hospital, New Haven, Connecticut, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Yale Cancer Center, New Haven, Connecticut, United States
University of Texas Southwestern Medical Center (UTSW), Dallas, Texas, United States
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Priscilla Brastianos, Boston, Massachusetts, United States
Hôpital Avicenne, Bobigny, France
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.